Limits...
Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.

Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F - PLoS ONE (2013)

Bottom Line: During the three-year evolution of PD, R2* increased in Substantia nigra (SN) (by 10.2% in pars compacta, p = 0.001, and 8.1% in pars reticulata, p = 0.013) and in the caudal putamen (11.4%, p = 0.011), without significant change in controls.Significant variation of R2* was longitudinally observed in the SN and caudal putamen of patients with PD evolving over a three-year period, emphasizing its interest as a biomarker of disease progression.Our results suggest that R2* MRI follow-up could be an interesting tool for individual assessment of neurodegeneration due to PD, and also be useful for testing the efficiency of disease-modifying treatments.

View Article: PubMed Central - PubMed

Affiliation: CHU Clermont-Ferrand, Service de Neurologie A, Clermont-Ferrand, France. mulla@chu-clermontferrand.fr

ABSTRACT

Purpose: To study changes of iron content in basal ganglia in Parkinson's disease (PD) through a three-year longitudinal follow-up of the effective transverse relaxation rate R2*, a validated MRI marker of brain iron content which can be rapidly measured under clinical conditions.

Methods: Twenty-seven PD patients and 26 controls were investigated by a first MRI (t0). Longitudinal analysis was conducted among the 18 controls and 14 PD patients who underwent a second MRI (t1) 3 years after. The imaging protocol consisted in 6 gradient echo images obtained at different echo-times for mapping R2*. Quantitative exploration of basal ganglia was performed by measuring the variation of R2* [R2*(t1) - R2*(t0)] in several regions of interest.

Results: During the three-year evolution of PD, R2* increased in Substantia nigra (SN) (by 10.2% in pars compacta, p = 0.001, and 8.1% in pars reticulata, p = 0.013) and in the caudal putamen (11.4%, p = 0.011), without significant change in controls. Furthermore, we showed a positive correlation between the variation of R2* and the worsening of motor symptoms of PD (p = 0.028).

Conclusion: Significant variation of R2* was longitudinally observed in the SN and caudal putamen of patients with PD evolving over a three-year period, emphasizing its interest as a biomarker of disease progression. Our results suggest that R2* MRI follow-up could be an interesting tool for individual assessment of neurodegeneration due to PD, and also be useful for testing the efficiency of disease-modifying treatments.

Show MeSH

Related in: MedlinePlus

R2* (s−1) at t0 in each ROI (mean ± standard error) in PD patients and controls.GM = gray matter; GP = Globus Pallidus; SNc = Substantia nigra pars compacta; SNr = Substantia nigra pars reticulata; WM = white matter; rPut = rostral putamen; cPut = caudal putamen. **: p<0.001; *: p<0.05; analysis of variance (ANOVA).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585727&req=5

pone-0057904-g002: R2* (s−1) at t0 in each ROI (mean ± standard error) in PD patients and controls.GM = gray matter; GP = Globus Pallidus; SNc = Substantia nigra pars compacta; SNr = Substantia nigra pars reticulata; WM = white matter; rPut = rostral putamen; cPut = caudal putamen. **: p<0.001; *: p<0.05; analysis of variance (ANOVA).

Mentions: Finally, the intergroup comparison at t0 with ANOVA showed a significant effect of PD on R2* in SNr (f = 6.55, p = 0.013) and SNc (f = 15.49, p<0.001), R2* being higher in the PD group. Also, R2* tended to be lower in the WM of PD patients (f = 3.08, p = 0.085) (Figure 2).


Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.

Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F - PLoS ONE (2013)

R2* (s−1) at t0 in each ROI (mean ± standard error) in PD patients and controls.GM = gray matter; GP = Globus Pallidus; SNc = Substantia nigra pars compacta; SNr = Substantia nigra pars reticulata; WM = white matter; rPut = rostral putamen; cPut = caudal putamen. **: p<0.001; *: p<0.05; analysis of variance (ANOVA).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585727&req=5

pone-0057904-g002: R2* (s−1) at t0 in each ROI (mean ± standard error) in PD patients and controls.GM = gray matter; GP = Globus Pallidus; SNc = Substantia nigra pars compacta; SNr = Substantia nigra pars reticulata; WM = white matter; rPut = rostral putamen; cPut = caudal putamen. **: p<0.001; *: p<0.05; analysis of variance (ANOVA).
Mentions: Finally, the intergroup comparison at t0 with ANOVA showed a significant effect of PD on R2* in SNr (f = 6.55, p = 0.013) and SNc (f = 15.49, p<0.001), R2* being higher in the PD group. Also, R2* tended to be lower in the WM of PD patients (f = 3.08, p = 0.085) (Figure 2).

Bottom Line: During the three-year evolution of PD, R2* increased in Substantia nigra (SN) (by 10.2% in pars compacta, p = 0.001, and 8.1% in pars reticulata, p = 0.013) and in the caudal putamen (11.4%, p = 0.011), without significant change in controls.Significant variation of R2* was longitudinally observed in the SN and caudal putamen of patients with PD evolving over a three-year period, emphasizing its interest as a biomarker of disease progression.Our results suggest that R2* MRI follow-up could be an interesting tool for individual assessment of neurodegeneration due to PD, and also be useful for testing the efficiency of disease-modifying treatments.

View Article: PubMed Central - PubMed

Affiliation: CHU Clermont-Ferrand, Service de Neurologie A, Clermont-Ferrand, France. mulla@chu-clermontferrand.fr

ABSTRACT

Purpose: To study changes of iron content in basal ganglia in Parkinson's disease (PD) through a three-year longitudinal follow-up of the effective transverse relaxation rate R2*, a validated MRI marker of brain iron content which can be rapidly measured under clinical conditions.

Methods: Twenty-seven PD patients and 26 controls were investigated by a first MRI (t0). Longitudinal analysis was conducted among the 18 controls and 14 PD patients who underwent a second MRI (t1) 3 years after. The imaging protocol consisted in 6 gradient echo images obtained at different echo-times for mapping R2*. Quantitative exploration of basal ganglia was performed by measuring the variation of R2* [R2*(t1) - R2*(t0)] in several regions of interest.

Results: During the three-year evolution of PD, R2* increased in Substantia nigra (SN) (by 10.2% in pars compacta, p = 0.001, and 8.1% in pars reticulata, p = 0.013) and in the caudal putamen (11.4%, p = 0.011), without significant change in controls. Furthermore, we showed a positive correlation between the variation of R2* and the worsening of motor symptoms of PD (p = 0.028).

Conclusion: Significant variation of R2* was longitudinally observed in the SN and caudal putamen of patients with PD evolving over a three-year period, emphasizing its interest as a biomarker of disease progression. Our results suggest that R2* MRI follow-up could be an interesting tool for individual assessment of neurodegeneration due to PD, and also be useful for testing the efficiency of disease-modifying treatments.

Show MeSH
Related in: MedlinePlus